Form 8-K - Current report:
SEC Accession No. 0000950170-21-000432
Filing Date
2021-07-07
Accepted
2021-07-07 07:31:02
Documents
14
Period of Report
2021-07-02
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K impl-20210702.htm   iXBRL 8-K 70131
2 EX-99.1 impl-20210702ex99_1.htm EX-99.1 21396
3 GRAPHIC img156313483_0.jpg GRAPHIC 89574
  Complete submission text file 0000950170-21-000432.txt   351845

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT impl-20210702.xsd EX-101.SCH 2431
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT impl-20210702_pre.xml EX-101.PRE 11617
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT impl-20210702_lab.xml EX-101.LAB 18193
7 EXTRACTED XBRL INSTANCE DOCUMENT impl-20210702_htm.xml XML 4895
Mailing Address 201 ELLIOTT AVE. W SUITE 260 SEATTLE WA 98119
Business Address 201 ELLIOTT AVE. W SUITE 260 SEATTLE WA 98119 206-568-1466
IMPEL NEUROPHARMA INC (Filer) CIK: 0001445499 (see all company filings)

EIN.: 263058238 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40353 | Film No.: 211076225
SIC: 2834 Pharmaceutical Preparations